Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 79 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

79 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 79 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

79 programs

Clinical programs

Page 1 of 2

  1. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  2. Alogabat

    Hoffmann-La Roche

    Angelman Syndrome

    phase 2 small molecule completed

    1 trial

  3. Atezolizumab

    Hoffmann-La Roche

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  4. BC45538

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  5. BN44619

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  6. BN45398

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy (DMD)

    phase 2 other active

    1 trial

  7. BO25430

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  8. BO39610

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  9. BO41932

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  10. BO42533

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  11. BO43249

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  12. BO43936

    Hoffmann-La Roche

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  13. BO44157

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  14. BO44178

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  15. BO44426

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. BO45853

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  17. BP39144

    Hoffmann-La Roche

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  18. BP41072

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  19. BP42155

    Hoffmann-La Roche

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  20. BP42772

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  21. BP44745

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  22. BP45381

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  23. BP45703

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  24. BP46016

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  25. CN45320

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial

  26. CO40115

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  27. CO40778

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  28. CO41942

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  29. CO43476

    Hoffmann-La Roche

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  30. CO43810

    Hoffmann-La Roche

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  31. CO43923

    Hoffmann-La Roche

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  32. CO45813

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  33. CO46274

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  34. Cetuximab

    Hoffmann-La Roche

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  35. Cobimetinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  36. Copegus

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  37. Delandistrogene moxeparvovec-rokl

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  38. Entrectinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule active

    1 trial

  39. Entrectinib

    Hoffmann-La Roche

    Breast Cancer

    phase 2 small molecule active

    1 trial

  40. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  41. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  42. GN43271

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  43. GO40516

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  44. GO40554

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  45. GO42216

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  46. GO43075

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  47. GO44096

    Hoffmann-La Roche

    Solid Tumors

    phase 2 other active

    1 trial

  48. GO45434

    Hoffmann-La Roche

    Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

79 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.